ArticleThe Journal of infectious diseases2019
Could the Drug Tafenoquine Revolutionize Treatment of Babesia microti Infection?
Article in The Journal of infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 48 citations in OpenAlex.
- A Two-Phase Approach to the Use of Tafenoquine Was Associated with Cure of Babesiosis in Two Immunocompromised Patients with Relapsing Babesiosis.Pathogens (Basel, Switzerland) · 2026Article
- Tafenoquine: A Breakthrough Option for Babesiosis Treatment.Tropical medicine and infectious disease · 2026Article
- Preassembled complexes of hAgo2 and ssRNA delivered by nanoparticles: a novel silencing gene expression approach overcoming the absence of the canonical pathway of siRNA processing in the apicomplexan parasite Babesia microti, blood parasite of veterinary and zoonotic importance.Emerging microbes & infections · 2025Article
- Article
- Evaluating Antimalarial Proteasome Inhibitors for Efficacy inACS omega · 2024Article
- Tafenoquine for Relapsing Babesiosis: A Case Series.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Article
- Comparative chemical genomics inProceedings of the National Academy of Sciences of the United States of America · 2024Article
- Tafenoquine-Atovaquone Combination Achieves Radical Cure and Confers Sterile Immunity in Experimental Models of Human Babesiosis.The Journal of infectious diseases · 2024Article
- Article
- Plasma Blood Levels of Tafenoquine following a Single Oral Dosage in BALBc Mice with AcutePathogens (Basel, Switzerland) · 2023Article
- The roles of COX-2 in protozoan infection.Frontiers in immunology · 2023Review
- Article
- Efficacy of the Antimalarial MMV390048 againstAntimicrobial agents and chemotherapy · 2022Article
- Repurposing of the Malaria Box for Babesia microti in mice identifies novel active scaffolds against piroplasmosis.Parasites & vectors · 2022Article
- Failure of an Approximately Six Week Course of Tafenoquine to Completely EradicatePathogens (Basel, Switzerland) · 2022Article
- Inhibitory effect of naphthoquine phosphate on Babesia gibsoni in vitro and Babesia rodhaini in vivo.Parasites & vectors · 2022Article
- Phosphatidylinositol 4-kinase is a viable target for the radical cure ofFrontiers in cellular and infection microbiology · 2022Article
- Tafenoquine exhibits broad spectrum antifungal activity at clinically relevant concentrationsNew microbes and new infections · 2022Article
- Article
- Treatment of Human Babesiosis: Then and Now.Pathogens (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
backgroundTafenoquine (TQ) was recently approved by the US Food and Drug Administration for prophylaxis of malaria and, in addition, for eradication of the hepatic phase of the relevant Plasmodium species. In this study, we evaluated the efficacy of TQ for treatment of Babesia microti infection in mice with severe combined immunodeficiency (SCID).
methodsSCID mice were infected with 1.1-1.5 × 108 B. microti-infected red blood cells by intraperitoneal injection. On day 3 or 4 postinfection, when parasitemia levels typically exceeded 10%, mice were treated with TQ vs vehicle alone, both administered by oral gavage.
resultsA single dose of TQ completely eliminated detectable parasites, with a >90% reduction in the level of parasitemia within just 4 days. Before elimination, a conspicuous phenotypic change in the parasite was observed. Although parasitologic cure was not achieved, there was no evidence for the development of drug resistance.
conclusionsThis study suggests that TQ may be a highly useful drug to treat B. microti infection in patients. If further animal studies establish that a marked reduction in B. microti parasitemia can be reliably achieved with peak blood levels of TQ known to be well tolerated in humans, a clinical trial in patients should be considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.